PER 1.27% 8.0¢ percheron therapeutics limited

For General Information, page-3227

  1. 720 Posts.
    lightbulb Created with Sketch. 210
    Agree with you on funding being the reason.

    Was there a phase2a study that predated your referenced phase 2 trial on Ionis-GHR-LRX (Cimdelirsen)?

    I quote this from the Ionis 2019 Ann Report, top of page 18: (https://ir.ionispharma.com/static-files/13a2c945-e305-4e72-917e-5582de2500ae)

    ”In November 2018, we initiated the Phase 2 proof-of-concept clinical study of IONIS-GHR-LRX in acromegaly patients. The study is randomised, double-blind, placebo-controlled, multi-center study on acromegaly patients uncontrolled on select long-acting somatostatin receptor ligands.”
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.0¢
Change
0.001(1.27%)
Mkt cap ! $82.94M
Open High Low Value Volume
8.0¢ 8.3¢ 7.9¢ $461.5K 5.711M

Buyers (Bids)

No. Vol. Price($)
6 844186 8.0¢
 

Sellers (Offers)

Price($) Vol. No.
8.2¢ 292500 1
View Market Depth
Last trade - 16.10pm 08/11/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.